|
1 Lin Q. Definition, diagnostic criteria and clinical types of cerebral palsy in children. Chin J Pediatr, 2005, 43(4)：262.[林庆. 小儿脑瘫的定义、 诊断条件及分型．中华儿科杂志，2005，43(4)：262.]
|
|
2 Lin Q, Li S, Liu JM, et al. The survey of morbidity and clinical types of cerebral palsy in 6 provinces in China. Chin J Pediatr, 2001, 39(10)：613–615.[林庆，李松，刘建蒙，等. 我国六省(区)小儿脑性瘫痪患病率及临床类型的调查分析. 中华儿科杂志，2001，39(10)：613–615.]
|
|
3 Yeargin M, Van Naarden Braun K, Doernberg NS, et al. Prevalence of cerebral palsy in 8–year–old children in three areas of the United States in 2002：A multisite collaboration. Pediatrics, 2008, 121(3)：547–554.
|
|
4 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta analysis. Stat Med, 2002, 21(11)：1539–1558.
|
|
5 Fu DL, Zhang Y, Tang J, et al. Clinical research of gangliosides on children with cerebral palsy. Med J Clin Exp Med, 2006, 9：1342.[傅大林，张跃，汤健，等．神经节苷脂治疗小儿脑性瘫痪临床研究．临床和实验医学杂志，2006, 9：1342.]
|
|
6 Cai SQ. Clinical research of gangliosides on children with cerebral palsy. World Health Digest, 2007, 4(4)：70–71.[柴书芹. 神经节苷脂治疗小儿脑性瘫痪临床研究．中外健康文摘．医药月刊，2007, 4(4)：70–71.]
|
|
7 Li W, Wang C, Wang Y, et al. Curative effect observation of gangliosides on children with cerebral palsy. Guizhou Med J, 2008, 32(8)：700–701.[李唯，王春，王燕，等. 神经节苷脂治疗小儿脑性瘫痪的疗效观察(附110例报告)．贵州医药，2008, 32(8)：700–701.]
|
|
8 Zhao QH, Zhao Y, Wu Y, et al. Effect of monosialo–gangliosides on cerebral palsy of childen. Chin J Rehabil Theory Pract, 2004, 10(7)：425–426.[张清华，赵勇，吴勇，等. 神经节苷酯治疗小儿脑性瘫痪临床观察．中国康复理论与实践，2004, 10(7)：425–426.]
|
|
9 Lenzi GL, Grigoletto F, Gent M, et al. Early treatment of stroke with monosialoganglioside GM–1. Efficacy and safety results of the early stroke trial. Stroke, 1994, 25(8)：1552–1558.
|
|
10 Argentino C, Sacchetti ML, Toni D, et al. GM–1 ganglioside therapy in acute ischemic stroke. Stroke, 1990, 21(5)：825.
|
|
11 Geisler FH, Coleman WP, Grieco G, et al. Measurements and recovery patterns in a multicenter study of acute spinal cord injury. Spine, 2001, 26(24 Suppl)：S68–86.
|
|
12 Schneider JS, Roeltgen DP, Rothblat DS, et al. GM–1 ganglioside treatment of Parkinson's disease：An open pilot study of safety and efficacy. Neurology, 1995, 45(6)：1149–1154.
|